These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36066750)

  • 1. Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study.
    Wendler J; Damann N; Röcken M; Teicher V; Schuier M; Hamann F; Schwenke H; Sieburg M; Behrens F
    Rheumatol Ther; 2022 Oct; 9(5):1435-1450. PubMed ID: 36066750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
    Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
    Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
    Azuaga AB; Frade-Sosa B; Laiz A; Estrada P; Prior-Español A; Horcada L; Polino L; Moreno M; Moragues C; Urruticoechea-Arana A; Sellas A; Tandaipan JL; Torrente-Segarra V; Garcia-Miguel J; Ros I; Ordoñez S; Moya P; Reina D; Mateo-Soria L; Fito C; Beltrán E; Pujol M; Cuervo AM; Cañete JD; Ramírez J;
    Clin Rheumatol; 2020 Oct; 39(10):2963-2971. PubMed ID: 32285259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
    Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
    Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; Li S; Wang Y; Mendelsohn AM; Song M; Zhu Y; Rahman P; McInnes IB;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1739-49. PubMed ID: 26097039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
    Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; You Y; Li S; Song M; Randazzo B; Rahman P; McInnes IB
    Ann Rheum Dis; 2016 Nov; 75(11):1984-1988. PubMed ID: 27098404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry.
    Rahman P; Arendse R; Khraishi M; Sholter D; Sheriff M; Rampakakis E; Lehman AJ; Nantel F
    BMJ Open; 2020 Aug; 10(8):e036245. PubMed ID: 32792436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
    Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
    Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
    Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
    Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
    Gottlieb A; Menter A; Mendelsohn A; Shen YK; Li S; Guzzo C; Fretzin S; Kunynetz R; Kavanaugh A
    Lancet; 2009 Feb; 373(9664):633-40. PubMed ID: 19217154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study.
    Dattola A; Balato A; Megna M; Gisondi P; Girolomoni G; De Simone C; Caldarola G; Cama E; Piaserico S; Fargnoli MC; Fidanza R; Parodi A; Burlando M; Offidani A; Diotallevi F; Potenza C; Conti A; Chiricozzi A; Campione E; Bianchi L
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2839-2845. PubMed ID: 32401377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
    J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
    Kavanaugh A; Ritchlin C; Rahman P; Puig L; Gottlieb AB; Li S; Wang Y; Noonan L; Brodmerkel C; Song M; Mendelsohn AM; McInnes IB;
    Ann Rheum Dis; 2014 Jun; 73(6):1000-6. PubMed ID: 24553909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.